Trial Profile
SAMSUNG MEDICAL CENTER
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 13 Jun 2022 Planned number of patients changed from 42 to 44.
- 13 Jun 2022 Planned End Date changed from 1 Feb 2023 to 14 Jun 2024.
- 13 Jun 2022 Planned primary completion date changed from 1 Feb 2022 to 14 Jun 2023.